Pierre,

 

On approval of DCVax-L by NWBO, if I had pancreatic, or many other serious cancers that were operable, I'd have the vaccine made from the tumor and administered off label.  If the cancer's inoperable, once NWBO initiates their DCVax-Direct trial I'd try to get into it.  The vaccines aren't curative by themselves, though survival is greatly improved in GBM, but perhaps more importantly, they are breaking down the blood/brain barrier so that drugs like Keytruda, which previously failed in GBM, are very effective.  UCLA in a variety of trials is achieving 50% or higher 5 year survival in trials that use DCVax-L along with a few different existing therapeutics.  As I understand it, in trials of DCVax-Direct many years ago they did have some positive results in pancreatic.  Sadly NWBO is a small biotech and waited further development of Direct until DCVax-L is generating revenue.  I expect approvals later this year and into next year dependent on when their automated FlaskWorks EDEN unit can be approved for commercial production.  Approval may come earlier in the U.K. with an approved manual production capability.

 

Gary